Phaseline

Companies › GenSight Biologics

GenSight Biologics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Ophthalmology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GS010 (lenadogene nolparvovec, Lumevoq)
AAV5-delivered ND4 gene replacement therapy for LHON
ND4Phase 2Leber Hereditary Optic DiseaseMay 2028
GS030-DP
Recombinant adeno-associated viral vector (rAAV2.7m8) delivering ChrimsonR-tdTomato gene f
CHRM5Phase 1Non-syndromic Retinitis PigmentosaOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03326336GS030-DPPhase 1Non-syndromic Retinitis PigmentosaOphthalmologyOct 2027
NCT07303296GS010 (lenadogene nolparvovec, Lumevoq)Phase 2Leber Hereditary Optic DiseaseOphthalmologyMay 2028

Targets

ND4 (1) CHRM5 (1)

Companies with the same targets

AstraZeneca

Companies built like this

jCyte NovaSight Emmecell Price Vision Group NexThera

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.